https://doi.org/10.4081/jbr.2025.12453
Multiple sclerosis: risk factors and therapies
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 9 June 2025
Multiple Sclerosis (MS) is a potentially progressive chronic autoimmune neurodegenerative disorder of the central nervous system, resulting from an autoimmune attack on the white matter. The main agents responsible for the development of MS involve exogenous, environmental, and genetic factors. The activation of the immune system triggers an inflammatory cascade at the level of nerve fibers and myelin. Regarding genetic predisposition, it is important to note that MS is not a hereditary disease. Infectious agents have also been studied as potential causes of the onset of MS. Several studies have shown that the Epstein-Barr Virus (EBV), responsible for mononucleosis, can influence the pathogenesis of MS, just as an altered mycobiome can play a role in triggering the pathology. Among the environmental factors, the prevalence of the disease observed as one moves away from the Equator is of particular etiopathogenetic relevance. This finding may be correlated with sun exposure and vitamin D (VD) levels. The aim of this article is to explore the complex risk factors and etiopathogenesis of MS, focusing on the interplay between genetic predisposition, environmental influences (such as VD deficiency and viral infections, particularly EBV), and the gut microbiome in the development and progression of the disease. This review was based on a comprehensive search of available medical and scientific literature, including observational studies (cohort, case-control, cross-sectional), metaanalyses, and systematic reviews, specifically addressing individuals with a confirmed MS diagnosis and studies related to genetic, environmental, or immunological risk factors. Studies that did not meet methodological standards, lacked relevant data, or were published in languages not understood by the authors were excluded.
Downloads
Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018;31:752-9. DOI: https://doi.org/10.1097/WCO.0000000000000622
Buzzard K, Chan WH, Kilpatrick T, Murray S. Multiple sclerosis: basic and clinical. In: Multiple Sclerosis: Advances in Clinical and Basic Research. Springer; 2017. p. 149-73. DOI: https://doi.org/10.1007/978-3-319-57193-5_8
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11. DOI: https://doi.org/10.1212/WNL.46.4.907
Weinshenker BG. The evolution of multiple sclerosis: natural history of multiple sclerosis. Ann Neurol 1994;36:S6-11. DOI: https://doi.org/10.1002/ana.410360704
Deangelis TM, Miller A. Diagnosis of multiple sclerosis. In: Multiple Sclerosis: A Comprehensive Textbook. 2nd ed. Elsevier; 2015. p. 159-68.
Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol 2019;26:27-40. DOI: https://doi.org/10.1111/ene.13819
Alwan S, Sadovnick AD. Multiple sclerosis and pregnancy: maternal considerations. Expert Rev Obstet Gynecol 2012;7:489-97. DOI: https://doi.org/10.2217/WHE.12.33
Jobin C, Larochelle C, Parpal H, et al. Gender issues in multiple sclerosis: an update. Women’s Health 2010;6:797-820. DOI: https://doi.org/10.2217/WHE.10.69
Nourbakhsh B, Mowry EM. Multiple sclerosis risk factors and pathogenesis. Curr Opin Neurol 2019;32:264-70. DOI: https://doi.org/10.1212/CON.0000000000000725
Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31. DOI: https://doi.org/10.1016/S0140-6736(02)08220-X
Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17. DOI: https://doi.org/10.1016/S0140-6736(08)61620-7
Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005;4:278-85. DOI: https://doi.org/10.1016/S1474-4422(05)70056-9
Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99. DOI: https://doi.org/10.1002/ana.21117
Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-501. DOI: https://doi.org/10.1001/jama.293.20.2496
Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:920-7. DOI: https://doi.org/10.1038/ni835
Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:1595-604. DOI: https://doi.org/10.1084/jem.20071030
Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunol 2014;3:e25. DOI: https://doi.org/10.1038/cti.2014.25
Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2008;197:73-81. DOI: https://doi.org/10.1086/523813
Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499–503. DOI: https://doi.org/10.1002/ana.20820
Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996;243:214–24. DOI: https://doi.org/10.1007/BF00868517
Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med 2018;50:1-14. DOI: https://doi.org/10.1038/s12276-018-0038-9
Chabas JF, Stephan D, Marqueste T, et al. Cholecalciferol (Vitamin D3) improves myelination and recovery after nerve injury. PLoS One 2013;8:e65034. DOI: https://doi.org/10.1371/journal.pone.0065034
Feige J, Moser T, Bieler L,et al. Vitamin D supplementation in multiple sclerosis: A critical analysis of potentials and threats. Neurol Res Pract 2020;2:14. DOI: https://doi.org/10.3390/nu12030783
Preiningerova JL, Zakostelska ZJ, Srinivasan A, et al. Multiple sclerosis and microbiome. Biomolecules 2022;12:433. DOI: https://doi.org/10.3390/biom12030433
Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A 2017;114:10719-24. DOI: https://doi.org/10.1073/pnas.1711233114
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.